Latest News

Fingolimod effective in all subgroups: analysis of phase III data

 

REPORT FROM THE 25TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 –

It takes 30 seconds

An analysis of data from the phase III FREEDOMS and TRANSFORMS trials indicates that oral fingolimod produces significant reductions in the rates of relapse and disease progression in subgroups of patients with different levels of disease activity (Havrdova et al. ECTRIMS 2011; abstract P473).

Read More

Targeting glutamate: the end of the monoamine hypothesis?

 

A number of recent papers have focused attention on the remarkable responses seen with glutamatergic agents in major depressive disorder (MDD), raising questions about the  monoamine hypothesis of psychiatric disorders that has dominated biological psychiatry for a half century (Schildkraut JJ. Am J Psychiatry 1965;122:509-522).

Read More

Mortality risk doubled in AD patients

 

The impact of Alzheimer’s disease on all-cause mortality has not been extensively examined but a new nested case-control study from Finland has now looked at this issue (Lonnroos et al. J Alzheimers Dis 2012; epublished August 22, 2012).

Read More

TOPICS: